NCT03238651View on ClinicalTrials.gov

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

August 17, 2020

Study Completion Date

August 17, 2020

Conditions
Lymphoma, Non-HodgkinLymphoma, Follicular, Marginal Zone
Interventions
DRUG

TAK-659

TAK-659 Tablets.

Trial Locations (4)

3080

Seoul National University Hospital, Seoul

6315

Samsung Medical Center, Seoul

460-0001

NHO Nagoya Medical Center, Nagoya

104-0045

National Cancer Center Hospital, Chuo-ku

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY

NCT03238651 - A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) | Biotech Hunter | Biotech Hunter